(Q35875096)

English

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.

scientific article published in December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

0 references

Gerd Fätkenheuer

4

object named as

Gerd Fätkenheuer

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

author name string

W David Hardy

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Roy M Gulick

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Howard Mayer

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Mark Nelson

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Jayvant Heera

6

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Natasa Rajicic

7

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

James Goodrich

8

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

language of work or name

0 references

publication date

1 December 2010

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Journal of Acquired Immune Deficiency Syndromes

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

55

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

558-564

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

27 July 2018

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

27 July 2018

Maraviroc for previously treated patients with R5 HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

27 July 2018

Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

27 July 2018

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

27 July 2018

CCR5 deficiency increases risk of symptomatic West Nile virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

27 July 2018

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

27 July 2018

Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

27 July 2018

Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

24 September 2018

The CCR5- 32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

24 September 2018

CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study Groups

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

24 September 2018

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3321258

24 September 2018

A DNA polymorphism at the alpha2-macroglobulin gene is associated with the severity of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20703158

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens

1 reference

https://pubmed.ncbi.nlm.nih.gov/20703158

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association between CCR5 genotype and the clinical course of HIV-1 infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20703158

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of rheumatoid arthritis with a functional chemokine receptor, CCR5

1 reference

https://pubmed.ncbi.nlm.nih.gov/20703158

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20703158

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

1 reference

https://pubmed.ncbi.nlm.nih.gov/20703158

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/QAI.0B013E3181EE3D82

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35875096&oldid=1522789295"